Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco (Q73806740)
Jump to navigation
Jump to search
scientific article published on 01 May 2000
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco |
scientific article published on 01 May 2000 |
Statements
Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group (English)
Cannon GW
Caldwell JR
Holt P
McLean B
Seidenberg B
Bolognese J
Ehrich E
Mukhopadhyay S